Late Stage Chronic Kidney Disease Drugs Market Growth Outlook Through 2024-2033

Overview and Scope
Late-stage chronic kidney disease drugs refer to medicines that treat end-stage chronic kidney disease. It improves a patient’s quality of life by halting the disease’s course and avoiding or postponing the need for dialysis or a transplant.

Sizing and Forecast
The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $6.38 billion in 2023 to $7.16 billion in 2024 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to improvements in diagnostic capabilities, aging population, increased prevalence of diabetes and hypertension, growing awareness of kidney diseases, expansion of pharmaceutical research and development..

The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $10.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to rising healthcare expenditure, adoption of precision medicine approaches, increasing focus on regenerative medicine, growing emphasis on patient-centered care, global initiatives for kidney disease awareness.. Major trends in the forecast period include expansion of regenerative medicine therapies, rise in telemedicine services for ckd management, development of combination therapies, emphasis on early intervention strategies, growing interest in biomarker-based diagnostics.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugs-global-market-report

Segmentation & Regional Insights
The late stage chronic kidney disease drugs market covered in this report is segmented –

1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

North America was the largest region in the late stage chronic kidney disease drugs market in 2023. The regions covered in the late stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12196&type=smp

Major Driver Impacting Market Growth
The high prevalence of chronic kidney diseases is expected to propel the growth of the late-stage chronic kidney disease drug market going forward. Chronic kidney diseases refer to a diverse range of conditions that affect the structure and operation of the kidneys. Late-stage chronic kidney disease drugs for chronic kidney disease are used to control blood pressure in patients and decrease protein loss to halt the progression of kidney impairment, manage symptoms, and avoid consequences. For instance, in July 2022, according to Centers for Disease Control and Prevention, a US-based Department of Health and Human Services, around 15%, or 37 million people in the US, were affected by kidney disease. The prevalence among individuals aged 45–64 is 12%, and people between 18 and 44 have the lowest majority of 6% in 2021. Therefore, the prevalence of chronic kidney disease is driving the growth of the late-stage chronic kidney disease drug market.

Key Industry Players
Major companies operating in the late stage chronic kidney disease drugs market report are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Evotec SE, Ionis Pharmaceuticals Inc., Akebia Therapeutics Inc., Ardelyx Inc., Concert Pharmaceuticals Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc, Shield Therapeutics Plc, Shire plc.

The late stage chronic kidney disease drugs market report table of contents includes:

1. Executive Summary
2. Late Stage Chronic Kidney Disease Drugs Market Characteristics
3. Late Stage Chronic Kidney Disease Drugs Market Trends And Strategies
4. Late Stage Chronic Kidney Disease Drugs Market – Macro Economic Scenario
5. Global Late Stage Chronic Kidney Disease Drugs Market Size and Growth
.
.
.
32. Global Late Stage Chronic Kidney Disease Drugs Market Competitive Benchmarking
33. Global Late Stage Chronic Kidney Disease Drugs Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Late Stage Chronic Kidney Disease Drugs Market
35. Late Stage Chronic Kidney Disease Drugs Market Future Outlook and Potential Analysis
36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model